Clinical Utility Trial for the SomaLogic CVD-T2D Test

NACompletedINTERVENTIONAL
Enrollment

251

Participants

Timeline

Start Date

March 15, 2022

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Cardiovascular DiseasesType 2 Diabetes
Interventions
OTHER

Educational Materials on the Cardiovascular Disease in Type 2 Diabetes (CVD-T2D)

Educational Materials will detail the diagnostic tests in question. This CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years.

OTHER

Educational Materials on the CVD-T2D and Bundled Metabolic Panel

Educational Materials will detail the diagnostic tests in question.his CVD-T2D will provide a numerical risk score for the likelihood of patients with type 2 diabetes to have a cardiovascular event in the next 4 years. The bundled metabolic scores will provide insight into the patient's current metabolic conditions.

Trial Locations (1)

94133

QURE Healthcare, San Francisco

All Listed Sponsors
collaborator

SomaLogic, Inc.

INDUSTRY

lead

Qure Healthcare, LLC

INDUSTRY